Global Consensus Renames PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS)
For almost a century, people have been told they have 'cysts on their ovaries' when the real problem was how their body handles insulin and hormones. An international panel now recommends a new name that points to that whole-body process instead of to harmless follicles on an ultrasound. The change matters because the old name steered care toward the pelvis and away from heart, liver, and diabetes risk. The proposed term is polyendocrine metabolic ovarian syndrome, or PMOS, in place of polycystic ovary syndrome (PCOS). The structures seen on ultrasound are immature follicles that paused development, not cysts that need surgery.
Based on reporting from International PCOS Consensus Consortium / Contemporary OB/GYN: International Consensus Recommends Renaming PCOS to Polyendocrine Metabolic Ovarian Syndrome.
If the word 'cysts' made you fear your ovaries, start here
Many people leave a first PCOS visit believing their ovaries are diseased, that they will need surgery, or that they will never conceive without a clinic. That fear is understandable. The name taught it.
The ultrasound picture that produced the name is usually not a set of pathological cysts. It is a row of immature follicles that have not been selected to ovulate. Up to 25% of people with regular cycles and normal androgen levels show a similar multifollicular look, and many people with severe metabolic symptoms have ordinary pelvic imaging.
An international consensus panel now recommends renaming the condition PMOS so care follows insulin, androgens, and long-term heart and liver risk. The short version: your ovaries are often the messenger, not the whole disease. The mechanism and lab list follow below.
Why the historical name pointed at the wrong organ
Polycystic ovary syndrome was described in 1935 and tied to how ovaries looked during surgery or ultrasound. That focus was incomplete. The fluid-filled structures are antral follicles that paused maturation because hormone signals were disrupted.
The old name also let clinicians diagnose from irregular cycles plus an ultrasound, then stop. Patients left with a pelvic story and no metabolic plan.
The Science Behind ItInsulin, androgens, and stalled ovulation
PMOS is a multi-organ endocrine and metabolic condition. In most patients the main driver is intrinsic insulin resistance, which can exist at any body mass index. Compensatory hyperinsulinemia (the pancreas making extra insulin) stimulates ovarian theca cells to overproduce androgens such as testosterone and androstenedione.
Higher insulin also suppresses hepatic sex hormone-binding globulin (SHBG), a liver protein that carries sex hormones in the blood. Less SHBG means more free, biologically active testosterone circulating.
Those shifts disrupt pulsatile gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH), which impairs follicle selection and regular ovulation. Chronic hyperinsulinemia and low-grade inflammation also raise long-term cardiovascular risk, dyslipidemia (unhealthy blood fats), endothelial stiffness, and hepatic steatosis (fat in the liver).
A useful analogy: the ovary is a dashboard light. The engine problem is how muscle and liver handle glucose.
Clinical Insight for ProvidersDo not stop at Rotterdam morphology
For more than two decades, the 2003 Rotterdam criteria allowed diagnosis with any two of three features: irregular or absent ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. In practice, that often meant irregular cycles plus an ultrasound and no metabolic panel.
The PMOS consensus framework requires a baseline metabolic assessment: fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), lipid subfractions, 2-hour oral glucose tolerance testing with paired insulin measurements, liver enzymes, plus total testosterone, free testosterone, and DHEA-sulfate.
The clinical goal is to find cardiovascular and metabolic risk in the twenties and thirties, not after gestational diabetes or hypertension appears. Combined oral contraceptives can protect the endometrium from hyperplasia (overgrowth of the uterine lining). They do not treat insulin resistance.
Certified Nurse-Midwives can order labs, start metformin or cycle-regulating therapy, counsel on myo-inositol and d-chiro-inositol, and refer to endocrinology or reproductive endocrinology when co-management is needed.
In Arizona: CNM metabolic and gynecologic care
In Arizona, Certified Nurse-Midwives are licensed Advanced Practice Registered Nurses with independent diagnostic and Schedule II through V prescriptive authority. They already treat PMOS as lifespan metabolic and gynecologic care, not a short visit for a birth-control pill.
Use the Arizona hub or directory if you want a hospital-affiliated clinic that can order the metabolic panel and manage metformin locally.
Fertility is often about ovulation, not empty ovaries
Patients are frequently told they will struggle with permanent infertility. That message causes unnecessary harm. The usual difficulty in PMOS is anovulation (not releasing an egg), not a depleted egg supply.
When insulin resistance and androgen excess improve, ovulatory function often resumes. Midwives can support basal body temperature charting, cervical mucus tracking, and luteal-phase progesterone testing to confirm ovulation.
For people planning pregnancy, earlier glucose optimization reduces early pregnancy loss, gestational diabetes, and preeclampsia. Reframing the condition as PMOS gives patients and clinicians a shared target before conception.
Questions this headline raises
The international consensus recommended PMOS (polyendocrine metabolic ovarian syndrome) because the condition is a systemic metabolic and endocrine disorder driven by insulin resistance, rather than an isolated ovary disease. The 'cysts' on ultrasound are normal immature follicles that paused development.